Monsenso (MONSO) H1 2025 earnings summary

Executive summary

• Revenue for H1 2025 was DKK 5,166k, a decrease from DKK 5,527k in H1 2024, with EBITDA at DKK -1,755k and EBIT at DKK -4,066k, both lower than the previous year.

• Cash flow from operations improved to DKK 666k from DKK -3,826k in H1 2024.

• Major digital research projects and commercial milestones were achieved, including a successful study with a global pharmaceutical company and a new public tender win in Spain.

Financial highlights

• Gross profit was DKK 1,909k, down from DKK 2,311k year-over-year.

• Cash and cash equivalents at period end were DKK 1,381k, compared to DKK 1,861k at FY 2024.

• Gross margin declined to 37% from 42% in H1 2024.

• Net loss for the period was DKK -3,839k, compared to DKK -3,231k in H1 2024.

• Market cap at period end was DKK 22.0m, down from DKK 31.5m.

Outlook and guidance

• Revenue for 2025 is expected to be DKK 12-13m, representing 8-16% growth.

• EBIT for 2025 is forecasted between DKK -7m and DKK -6m.

• Management expects sufficient liquidity for ongoing operations and anticipates new orders to support cash flow in late 2025.